On November 14, 2024, Invivyd, Inc., a biopharmaceutical company, reported its financial results for the third quarter ended September 30, 2024, and provided an update on recent business highlights. The company announced a net product revenue of $9.3 million for Q3 2024, a significant increase from $2.3 million in the previous quarter. Invivyd also reported having $106.9 million in cash and cash equivalents and is targeting near-term profitability within the first half of 2025. The company's PEMGARDA™ (pemivibart) Fact Sheet was updated to include data on the neutralization activity against current circulating COVID-19 variants, aligning with clinical trial data demonstrating protection against symptomatic COVID-19. Invivyd began dosing in a first-in-human clinical trial for its next-generation molecule VYD2311 in August 2024, with preliminary data expected in late Q4 2024. Additionally...Show More

On November 14, 2024, Invivyd, Inc., a biopharmaceutical company, reported its financial results for the third quarter ended September 30, 2024, and provided an update on recent business highlights. The company announced a net product revenue of $9.3 million for Q3 2024, a significant increase from $2.3 million in the previous quarter. Invivyd also reported having $106.9 million in cash and cash equivalents and is targeting near-term profitability within the first half of 2025. The company's PEMGARDA™ (pemivibart) Fact Sheet was updated to include data on the neutralization activity against current circulating COVID-19 variants, aligning with clinical trial data demonstrating protection against symptomatic COVID-19. Invivyd began dosing in a first-in-human clinical trial for its next-generation molecule VYD2311 in August 2024, with preliminary data expected in late Q4 2024. Additionally, Invivyd posted an updated corporate presentation on its website and issued a press release regarding the publication of a letter in the New England Journal of Medicine, which highlighted the immunobridging pathway leading to PEMGARDA's Emergency Use Authorization. The company's financial statements showed an increase in R&D expenses, consistent SG&A expenses, and a net loss of $60.7 million for the quarter.